STOCK TITAN
  1. Home
  2. News
  3. ERAS

Erasca Inc - ERAS STOCK NEWS

Welcome to our dedicated news page for Erasca (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Erasca's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Erasca's position in the market.

News
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS) announced three presentations at the 2024 ASCO Annual Meeting. The oral presentation will showcase updated HERKULES-3 results for ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer. Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for ERAS-601 and cetuximab in chordoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Rhea-AI Summary
Erasca, Inc. secures funding of $45 million through a private placement to extend cash runway until H2 2026, boosting its focus on precision oncology therapies for RAS/MAPK pathway-driven cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Rhea-AI Summary
Erasca, Inc. (ERAS) achieves global registrational clarity for naporafenib and reports key clinical milestones for naporafenib, ERAS-007, and ERAS-801. The company anticipates multiple data readouts in 2024 and plans to initiate the pivotal SEACRAFT-2 trial. Erasca has a strong balance sheet with $322 million in cash, cash equivalents, and marketable securities as of December 31, 2023. Erasca's R&D update conference call and webcast are scheduled for March 28, 2024, at 8:30 am ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Rhea-AI Summary
Erasca, Inc. announces clinical trial collaboration agreements with Novartis for pan-RAF inhibitor naporafenib in combination with trametinib for RAS/MAPK pathway-driven tumors. SEACRAFT-1 Phase 1b data expected in 2024, SEACRAFT-2 initiation in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
clinical trial
-
News
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS) will participate in the 6th Annual Guggenheim Biotechnology Conference in New York, with the chairman and CEO, Jonathan E. Lim, and the CFO and chief business officer, David M. Chacko, taking part in a fireside chat and one-on-one investor meetings. The live audio webcast and archived replay of the event will be available on Erasca's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences
-
News
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS) to present at 42nd annual J.P. Morgan Healthcare Conference, with a focus on precision oncology therapies for RAS/MAPK pathway-driven cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences
News
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS) has announced that the FDA granted Fast Track Designation to naporafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on or are intolerant to anti‑programmed death-1 (ligand 1) (PD‑(L)1)-based regimen, and whose tumors contain an NRAS mutation. Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRAS-melanoma and other RAS/MAPK pathway-altered solid tumors. The company is rapidly advancing clinical development with the initiation of the pivotal Phase 3 SEACRAFT-2 trial expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
clinical trial
-
News
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
Rhea-AI Summary
Erasca, Inc. (ERAS) announces program updates for naporafenib and ERAS-801, extending cash runway to H1 2026. The company gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma, completed dose escalation and identified MTD for ERAS-801, supporting enrollment of expansion cohorts in recurrent GBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.38%
Tags
none
-
News
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS) reported financial results for the fiscal quarter ended September 30, 2023, and provided updates on their clinical programs. The company dosed the first patient with naporafenib plus trametinib in their SEACRAFT-1 Phase 1b trial and identified promising activity in the HERKULES-3 signal-seeking study of ERAS-007 in combination with encorafenib and cetuximab in EC-naïve patients with BRAF-mutated colorectal cancer. The company's balance sheet shows a strong position with $344 million in cash, cash equivalents, and marketable securities as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Erasca to Present at Upcoming Investor Conferences in November
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS) will participate in investor conferences in November 2023, including Jefferies London Healthcare Conference and 6th Annual Evercore ISI HealthCONx Conference. Webcasts and one-on-one investor meetings are planned. The company focuses on therapies for RAS/MAPK pathway-driven cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences
Stock ERAS logo
Erasca Inc

Nasdaq:ERAS

ERAS Rankings

#3452 Ranked by Market Cap
#5244 Ranked by Stock Gains
N/A Ranked by Dividends

ERAS Stock Data

319.65M
85.72M
20.34%
47.39%
5.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ERAS

our mission at erasca is embedded in our name: to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. we have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.